Interleukin-2 (IL-2) is a critical cytokine for the homeostasis and function of forkhead box p3-expressing regulatory T cells (Foxp3 + Tregs). Dysregulation of the IL-2-IL-2 receptor axis is associated with aberrant Foxp3
+ Tregs and T cell-mediated autoimmune diseases such as type 1 diabetes. Treatment with recombinant IL-2 has been reported to enhance Foxp3 + Tregs and suppress different models of autoimmunity. However, efficacy of IL-2 therapy is dependent on achieving sufficient levels of IL-2 to boost tissue-resident Foxp3 + Tregs while avoiding the potential toxic effects of systemic IL-2. With this in mind, adenoassociated virus (AAV) vector gene delivery was used to localize IL-2 expression to the islets of NOD mice. Injection of a doublestranded AAV vector encoding IL-2 driven by a mouse insulin promoter (dsAAVmIP-IL2) increased Foxp3 + Tregs in the islets but not the draining pancreatic lymph nodes. Islet Foxp3 + Tregs in dsAAVmIP-IL2-treated NOD mice exhibited enhanced fitness marked by increased expression of Bcl-2, proliferation, and suppressor function. In contrast, ectopic IL-2 had no significant effect on conventional islet-infiltrating effector T cells. Notably, b-cell-specific IL-2 expression suppressed late preclinical type 1 diabetes in NOD mice. Collectively, these findings demonstrate that b-cell-specific IL-2 expands an islet-resident Foxp3 + Tregs pool that effectively suppresses ongoing type 1 diabetes long term. Diabetes 62: [3775] [3776] [3777] [3778] [3779] [3780] [3781] [3782] [3783] [3784] 2013 T ype 1 diabetes is a T-cell-mediated autoimmune disease in which the insulin-producing b-cells in the pancreatic islets of Langerhans are destroyed (1) (2) (3) . Studies in at-risk individuals, type 1 diabetic patients, and NOD mice have shown that the breakdown in b-cell-specific T-cell tolerance is multifactorial, leading to impaired peripheral immunoregulation (1) (2) (3) . The diabetogenic response is characterized by a progressive but nondestructive infiltration of the islets by CD4 + and CD8 + effector T cells (Teffs), forkhead box p3-expressing Tregs (Foxp3 + Tregs), and other immune effectors in NOD mice (4) . This innocuous insulitis then progresses to a destructive stage, leading to b-cell depletion and clinical type 1 diabetes. Recently, it has become evident that the transition to destructive insulitis is in part due to impaired islet-resident Foxp3 + Tregs in NOD mice (5) (6) (7) (8) . Foxp3 + Tregs are dependent on interleukin-2 (IL-2) for maintenance of Foxp3 gene expression, survival, proliferation, and suppressor function (9) (10) (11) (12) (15) (16) (17) . In contrast, FOXP3 + Tregs obtained from peripheral blood of type 1 diabetic patients exhibit deficient IL-2R signaling in vitro, evident by reduced phosphorylation of signal tranducer and activator of transcription 5 (pSTAT5), a transcription factor that regulates Foxp3 + Treg-dependent genes (21) .
In view of the potent effects of IL-2 on Foxp3 + Tregs, recombinant (r)IL-2 therapy has garnered significant interest for the treatment of chronic inflammation, transplantation, and autoimmunity. The pleiotropic and potentially toxic effects resulting from IL-2 stimulation of conventional T cells and other immune effectors has led to systemic administration of low doses of rIL-2. Low-dose rIL-2 therapy exploits the ability of Foxp3 + Tregs, which constitutively express CD25 and the corresponding high-affinity IL-2R, to outcompete other immune effectors when IL-2 is limiting (22) . Clinical studies have shown that low-dose rIL-2 therapy is protective in graft-versus-host disease and hepatitis C virus-induced vasculitis (23, 24) . In addition, b-cell autoimmunity is prevented and/or suppressed in NOD mice following treatment with low-dose rIL-2, rIL-2-anti-IL-2 antibody complexes, or a tetracycline-inducible adenoassociated virus (AAV) vector expressing IL-2 systemically by enhancing the Foxp3 + Treg pool (16, (25) (26) (27) (28) (29) . A recent phase I/II trial testing rIL-2 and rapamycin in type 1 diabetic patients, however, reported only a transient increase in FOXP3 + Tregs (30) , possibly reflecting the need for elevated and persistent levels of IL-2. Furthermore, treatment resulted in an increase in activated natural killer (NK) cells and eosinophils and an accelerated loss of insulin C-peptide levels, suggesting exacerbated b-cell autoimmunity. These clinical findings highlight the potential therapeutic benefit as well as the difficulty in achieving a balance between efficacy and the unwanted pleiotropic and systemic activity of IL-2. Accordingly, we have assessed the use of AAV vectors to increase local IL-2 levels in the islets and enhance the resident Foxp3 + Treg pool in vivo. AAV vectors are nonreplicating, noncytopathic, nonintegrating, and arguably the most effective and safe strategy to deliver genes in vivo (31) . Indeed, AAV vectors have been successfully applied in the clinic to complement various genetic disorders (32) (33) (34) . AAV vectors transduce both dividing and nondividing cells, and the availability of several serotypes and newly engineered vectors permit targeting of a broad range of cell types and tissues in vivo. Furthermore, selective transgene expression can be achieved with cell-specific promoters (35, 36) . Coupled with the development of self-complementary or double stranded (ds)AAV vectors (37, 38) , as well as the recent advances in manufacturing and purification, AAV vectors provide an approach to sustain long-term transgene expression in vivo. In the current study, we demonstrate that dsAAV vector-mediated IL-2 expression by b-cells selectively increases the frequency and function of islet Foxp3 + Tregs to effectively suppress type 1 diabetes long-term.
RESEARCH DESIGN AND METHODS
Mice. NOD/LtJ, NOD.CB17-Prkdcscid/J (NOD.scid), NOD.Ca
GFP (40) , and NOD.8.3 (41) mice were bred and maintained under specific pathogen-free conditions in an American Association for Laboratory Accreditation-accredited animal facility. NOD mice were diagnosed as diabetic after three consecutive blood glucose readings .250 mg/ dL. All procedures were approved by the University of North Carolina Animal Use and Care Committee. dsAAV vector engineering, packaging, and vaccination. Full-length cDNA encoding murine Il2 (of the NOD genotype) and EGFP were subcloned into a dsAAV plasmid (37) containing the murine preproinsulin II promoter (mIP). dsAAV vector packaging was carried out as previously described (42) . Briefly, HEK 293T cells were cotransfected via polyethyleneimine with adeno helper plasmid (pXX6-80), AAV8 capsid plasmid, and dsAAVmIP-IL2/enhanced green fluorescent protein (EGFP) plasmid. Nuclear fractions were harvested 72 h posttransfection and packaged vector purified with a Cesium Chloride (RPI Corp.) gradient. Vector containing fractions and titers were determined by Southern dot blot. NOD mice were vaccinated intraperitoneally with dsAAV8mIP-IL2 or dsAAV8mIP-EGFP. ELISA. The anti-IL-2 antibody set (JES6-1 and JES6-5; eBioscience) was used at a concentration of 2 mg/mL on a high binding ELISA plate (Costar) to measure IL-2 levels in serum and islet cultures. Interferon-g (IFN-g) was measured with the mouse IFN-g ELISA set (BD optEIA; BD Biosciences) as per the manufacturer's recommendations. Islet isolation and streptozotocin treatment. Pancreases were perfused with 2 mg/mL collagenase P (Roche) and digested for 30 min at 37°C. Islets were purified via Ficoll gradient, handpicked, and counted. For flow cytometry analysis, lymphocytes were collected from freshly isolated islets after culturing in RMPI complete medium for a minimum of 4 h at 37°C and filtered through a 70-micron nylon mesh.
NOD mice were treated intraperitoneally with 200 mg/kg of streptozotocin (STZ; Sigma-Aldrich), resuspended in fresh sodium citrate buffer (pH 4.0), and 72 h later vaccinated intraperitoneally with AAV8mIP-IL2 or left untreated. Blood glucose levels and serum IL-2 were assessed over 10 days post-rAAV vector vaccination. Flow cytometry. Cells from various tissues were stained with previously titrated fluorochrome-conjugated monoclonal antibodies specific for: CD3 (145-2C11), CD4 (GK1.5), CD8 (Ly-2), CD25 (PC61.5), CD62L (MEL-14), glucocorticoidinduced tumor necrosis factor receptor-related protein (GITR, DTA-1), inducible costimulator (ICOS, 7E.17G9), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, UC10-4F10-11), and Foxp3 (FJK-16s). Fc receptors were blocked with rat anti-mouse CD16/32 (2.4G2; BD Biosciences) prior to staining. Intracellular KI67 (B56; BD Biosciences) and Bcl-2 (3F11; BD Biosciences) staining was done using the Fix/Perm and Perm/Wash reagents (eBioscience) according to the manufacturer's recommendations.
Intracellular cytokine staining was performed on single-cell suspensions as previously described (43) . Briefly, lymphocytes were stimulated with 500 ng/mL phorbol myristic acid (Sigma-Aldrich) and 1,000 ng/mL ionomycin (Sigma-Aldrich) in complete RPMI medium for 5 h at 37°C and then treated with 10 mg/mL brefeldin A (Sigma-Aldrich) for 4 h. Cells were stained for surface molecules, fixed, and permeabilized with Cytofix/Cytoperm (BD Biosciences) and stained for intracellular IFN-g (XMG1.2) or IL-10 (JES5-16E3). For pSTAT5 staining, tissues were immediately processed in PBS containing 2% paraformaldehyde. Single-cell suspensions were incubated on ice for 20 min, centrifuged, and resuspended in ice-cold methanol for 30 min. Cells were then counted, washed twice in 1% BSA in PBS, and stained with anti-pSTAT5 antibody ( 
RESULTS

b-Cell-expressed IL-2 increases islet Foxp3
+ Tregs. To target transgene expression to b-cells, dsAAV8mIP-IL2 encoding IL-2 driven by mIP was engineered. The serotype capsid 8 protein used to package the AAV vector has b-cell-specific tropism (35, 36) . IL-2 was detected in cultures of islets prepared from NOD.scid mice injected intraperitoneally with dsAAV8mIP-IL2, confirming ectopic IL-2 expression by b-cells in vivo (Fig. 1A) . No IL-2 was observed in supernatants from single-cell suspensions of liver or heart (data not shown), which are major tissues transduced in vivo by AAV8 vectors (44) . Persistent low levels of IL-2 were detected in the serum of 10-12-week-old NOD female mice treated with dsAAV8mIP-IL2 (Fig. 1B) . Reduction of b-cell mass by STZ injection prior to dsAAV8-mIP-IL2 vaccination significantly decreased serum IL-2 levels (Fig. 1C) , further indicating ectopic IL-2 expression by b-cells in vivo. No difference in the frequency of conventional CD4 + and CD8 + T cells, B cells (CD19 + B220 + ), and NK cells (DX5 + ) was detected in the blood of dsAAV8mIP-IL2-vaccinated animals compared with control groups (Fig. 1D) .
The effect of increased local IL-2 on islet and PLN Foxp3 + Tregs was examined in 12-week-old NOD female mice 4 weeks after dsAAV8mIP-IL2 treatment. The frequency and number of islet Foxp3 + Tregs were increased up to two-fold in NOD mice treated with dsAAV8mIP-IL2 compared with animals injected with dsAAV8mIP-EGFP or left untreated ( Fig. 2A and B) . Notably, no significant effect on PLN Foxp3 + Tregs was detected after treatment ( Fig. 2A and B) , suggesting that dsAAV8mIP-IL2 administration preferentially affected islet Foxp3 + Tregs. Phenotypic analyses demonstrated that the frequency of islet CD62L HI Foxp3 + Tregs was significantly increased in dsAAV8mIP-IL2-treated versus control animals (Fig.  2C ). In addition, the level of CD25 expression by islet Foxp3 + Tregs, based on mean fluorescence intensity, was elevated in a dsAAV8mIP-IL2 dose-dependent manner ( Fig. 2A and D) . In contrast, the frequency of islet Foxp3 + Treg-expressing CTLA-4, GITR, and ICOS and the levels of expression of the respective molecules were similar between the dsAAV8mIP-IL2 and control groups (Supplementary Fig. 1 ). Unlike the islets, the phenotype of PLN Foxp3 + Tregs was unaffected by dsAAV8mIP-IL2 vaccination (Fig. 2) .
In contrast to islet Foxp3 + and CD8 + Teffs was detected in the islets of dsAAV8mIP-IL2-treated NOD mice (Fig. 2E ) . However, the ratio between the pool of IFN-g + Teffs and Foxp3 + Tregs in the islets but not PLNs was decreased in dsAAV8mIP-IL2 versus untreated and dsAAV8mIP-EGFP cohorts (Fig. 2F) .
To determine if the increased islet Foxp3 + Treg pool correlated with elevated IL-2R signaling, levels of pSTAT5 were measured. Up to 50% of islet Foxp3 + Tregs were pSTAT5 + , reflecting an ;10-fold increase in dsAAV8mIP-IL2 versus control groups (Fig. 3A) . Only a modest two-fold 10 VPs dsAAV8mIP-IL2 (6.4 6 1.1%) relative to control animals (3.6 6 0.6%) (Fig. 3B) . In contrast, levels of pSTAT5 detected in Foxp3 
CD4
+ T cells in the PLNs were unaffected by b-cellspecific IL-2 (Fig. 3) . Together, these findings demonstrate that b-cell-specific IL-2 expression results in an increased pool of phenotypically distinct islet but not PLN (Fig. 4B) . In contrast, Bcl-2 expression was unaffected in PLN Foxp3 + Tregs (Fig. 4A and B) or in islet IFN-g + CD4
+ and CD8 + Teffs (Fig. 4C ) . Proliferation of islet and PLN Foxp3 + Tregs after dsAAV8mIP-IL2 administration was analyzed by KI67 staining. The frequency of KI67 + Foxp3 + CD25 + T cells was significantly increased in the islets by 8 days post-dsAAV8mIP-IL2 treatment (Fig. 4D) . In contrast, the frequency of KI67
+ T cells in the PLNs remained unchanged over time (Fig. 4D) , as was the frequency of KI67-staining islet IFN-g + CD4
+ and CD8 + Teffs (Fig. 4E ) . Next, the influence of b-cell-specific IL-2 on islet Foxp3 + Treg suppressor activity was assessed. NOD.BDC mice transgenic for a Foxp3-internal ribosome entry site-GFP reporter cassette (NOD.BDC. exhibited significantly increased suppressor activity compared with islet Foxp3 + Tregs isolated from dsAAV8mIP-EGFP donors at all ratios tested (Fig. 4F) . Together, these results demonstrate that b-cell-specific IL-2 enhances the fitness of islet Foxp3 + Tregs characterized by increased Bcl-2 expression, proliferation, and suppressor function. Type 1 diabetes is prevented at a late preclinical stage in NOD mice by b-cell-expressed IL-2. Since b-cellspecific IL-2 expression increased islet Foxp3 + Tregs, the efficacy of AAV8mIP-IL2 to suppress ongoing b-cell autoimmunity and prevent overt diabetes was examined. NOD female mice 12 or 16 weeks of age, representing late preclinical stages of type 1 diabetes, received a single intraperitoneal injection of dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or were left untreated, and diabetes was monitored. All NOD female mice treated with 2.5 3 10
10 VPs of dsAAV8mIP-IL2 at either 12 or 16 weeks of age remained diabetes-free (Fig. 5A and B) . Similarly, the frequency of diabetes was significantly reduced in NOD female mice treated at 12 weeks of age with 1 3 10 10 VPs of dsAAV8mIP-IL2 (2 of 8) relative to animals left untreated (18 of 22) or receiving 2.5 3 10
10 VPs dsAAV8mIP-EGFP (10 of 10) (Fig. 5A) . The latter indicated that diabetes protection was not attributed to a nonspecific effect of dsAAV vector transduction of b-cells.
Diabetes-free NOD mice at 35 weeks of age exhibited a higher frequency of islet Foxp3 + Tregs in dsAAV8mIP-IL2 versus control groups, while no marked difference in the PLNs was observed (Fig. 5C) . Furthermore, islet Foxp3 + Tregs of dsAAV8mIP-IL2-treated NOD mice were characterized by an increased frequency of CD62L
HI
Foxp3
+ Tregs (Fig. 5D) . Additionally, the ratio of IFN-g + Teffs to Foxp3 + Tregs was decreased in the islets of dsAAV8mIP-IL2-treated NOD mice compared with normoglycemic untreated controls (Fig. 5E) . No difference, however, was detected in the IFN-g + Teffs to Foxp3 + Tregs ratio for PLN of dsAAV8mIP-IL2-vaccinated animals (Fig. 5E ). These results demonstrate that b-cell-specific IL-2 expression effectively suppresses ongoing autoimmunity long-term by enhancing the islet Foxp3 + Treg survival and/or function in NOD mice and type 1 diabetic patients (9) (10) (11) (12) . Systemic administration of low-dose rIL-2 or IL-2-antibody complexes is effective in preventing ongoing b-cell autoimmunity in NOD mice (16, (25) (26) (27) (28) (29) . Nevertheless, achieving a protective versus proinflammatory response via systemic rIL-2 delivery can be problematic. For instance, systemic low-dose rIL-2 plus rapamycin resulted only in a transient increase in FOXP3 + Tregs in type 1 diabetic subjects, and b-cell function declined, suggesting exacerbated autoimmunity (30) . Our results demonstrate that dsAAV vector-mediated targeting of IL-2 expression to b-cells is an effective strategy to manipulate the islet Foxp3 + Treg pool and diabetogenic response, while avoiding complications associated with systemic delivery of rIL-2.
A key finding made in this study was the differential effect of b-cell-specific IL-2 on islet-infiltrating Foxp3 + Tregs and Teffs (Fig. 2) . Elevated local levels of IL-2 resulted in marked expansion of islet Foxp3 Tregs correlated with enhanced proliferation early after dsAAV8mIP-IL2 treatment (Fig. 4D) . Interestingly, islet Foxp3 + Tregs division was reduced compared with untreated animals 4 weeks post-dsAAV8mIP-IL2 vaccination (Fig. 4D) . This result suggests that homeostasis is achieved overtime within the Foxp3 + Treg pool despite increased local levels of IL-2 and elevated IL-2R signaling (Fig. 3) . Accordingly, long-term maintenance of islet Foxp3 + Tregs in dsAAV8mIP-IL2-treated animals ( Fig. 5C  and D) is likely due to enhanced survival, reflected by increased expression of anti-apoptotic Bcl-2 ( Fig. 4A) and Bcl-xL ( Supplementary Fig. 2 ) as opposed to persistent levels of elevated Foxp3 + Treg proliferation in the islets.
In addition to increasing the size of the pool, b-cellspecific IL-2 also induced qualitative changes in islet Foxp3 + Tregs. For instance, up to a four-fold increase in suppressor activity was detected in vitro by BDC peptidespecific islet Foxp3 + Tregs from dsAAV8mIP-IL2-treated NOD.BDC.Foxp3 GFP mice (Fig. 4F) . The latter may be explained by the approximate two-fold increase in the frequency of CD62L HI Foxp3 + Tregs in the islets of dsAAV8mIP-IL2-treated NOD mice (Fig. 2C) . We and others (6, 19, 46, 47) Tregs by b-cellexpressed IL-2 were sufficient to suppress ongoing b-cell autoimmunity at late preclinical stages and prevent the onset of diabetes long-term ( Fig. 5A and B) . Initial efforts to induce remission in recent-onset diabetic NOD mice by dsAAV8mIP-IL2 vaccination have proven to be unsuccessful ( Supplementary Fig. 3 ). The latter may be due to an insufficient b-cell pool that can be transduced, thereby limiting local levels of IL-2 ( Supplementary Fig. 3 ). It is noteworthy that the reduced ratio of Teffs to Foxp3 + Tregs and increased frequency of CD62L HI Foxp3 + Tregs in the islets observed 4 weeks post-dsAAV8mIP-IL2 vaccination (Fig. 2) were also evident in NOD mice monitored for diabetes long-term (e.g., up to 23 weeks after dsAAV vaccination) (Fig. 5 ). This result is particularly striking in view of the progressive increase in the Teffs to Foxp3 + Tregs ratio, as well as the declining frequency of CD62L
HI
Foxp3
+ Tregs apparent in the islets of 35-week-old control NOD female mice ( Fig. 5D and E) , typical of ongoing b-cell autoimmunity. These findings demonstrate that once established, the islet Foxp3 + Treg pool is maintained longterm by persistent b-cell-expressed IL-2. Indeed, similar numbers of islet Foxp3 + Tregs were detected in NOD mice treated 23 ( Supplementary Fig. 4) versus 4 weeks (Fig. 2B) FIG. 5. dsAAV8mIP-IL2 prevents diabetes in NOD mice at late preclinical stages. A: Ten-to 12-week-old NOD female mice were treated with 2.5 3 10 10 VPs (n = 9) or 1 3 10 10 VPs (n = 8) of dsAAV8mIP-IL2, 2.5 3 10 10 VPs of dsAAV8mIP-EGFP (n = 10), or left untreated (n = 22) and monitored for diabetes. *P < 0.05, ***P < 10
23
, Kaplan-Meier log-rank test. B: Fifteen-to 16-week-old NOD females were treated with 2.5 3 10 10 VPs (n = 5) dsAAV8mIP-IL2 or were left untreated (n = 5) and monitored for diabetes as in A. *P < 0.05, Kaplan-Meier log-rank test. C: At 35 weeks of age, the frequency of Foxp3
+ T cells in the islets and PLNs of NOD mice from A. *P < 0.05, ***P < 10
, two-way ANOVA 6 SEM. D: Islet Foxp3 + CD25 + CD4 + T cells were assessed for CD62L expression. *P < 0.05, ***P < 10
, one-way ANOVA 6 SEM. E: The ratio of IFN-g + Teffs to Foxp3 + Tregs was compared between treatment groups in the PLNs and islets. *P < 0.05, **P < 10
22
, two-way ANOVA 6 SEM.
AAV VECTOR-MEDIATED MODIFICATION OF b-CELLS
post-dsAAVmIP-IL2 vaccination. Whether expression of b-cell-specific IL-2 is required to maintain islet Foxp3 +-Tregs needs to be determined. Interestingly, dsAAV8mIP-IL2 failed to prevent diabetes in transgenic NOD.8.3 mice expressing the H2K d -restricted T-cell receptor specific for islet-specific glucose-6-phosphatase catalytic subunitrelated protein ( Supplementary Fig. 5 ), suggesting that Foxp3 + Tregs are required for disease prevention; for instance, CD4 + Foxp3 + Tregs make up only ,1% of the islet T cell pool following dsAAV8mIP-IL2 vaccination.
This study further highlights the efficacy of dsAAV vector-mediated gene transfer to selectively modify the immunogenicity of b-cells in vivo. Transduction of b-cells in vivo with a dsAAV vector results in rapid transgene expression that persists long-term (Fig. 1B) ; the latter indirectly demonstrating that b-cell viability and function are unaffected by dsAAV vector transduction. The use of an insulin promoter restricts transgene expression to b-cells, so that high local cytokine levels can be obtained within the islets and complications associated with systemic cytokine delivery minimized (30) . A similar approach has been taken to target ectopic IL-4 expression to b-cells (35) . Recent technological advances can also be exploited to refine b-cell specificity and reduce immunogenicity of AAV capsid proteins, thereby enhancing application of dsAAV vector gene transfer for the treatment of type 1 diabetes in the clinic (48) .
Our observations are consistent with a model in which elevated local IL-2 has direct effects on islet Foxp3 + Tregs, only minimal (if any) on islet Teffs, and no effect on non-T cell islet residents such as NK cells and B cells (Supplementary Fig. 6 ). An increased pool of islet 
Foxp3
+ Tregs and increased fitness and suppressor function effectively blocks ongoing b-cell destruction by Teffs. Once established, the islet Foxp3 + Treg pool is stable and long-term tolerance maintained. These results provide strong rationale to further pursue b-cell-specific targeting of IL-2 and other cytokines as a strategy to manipulate islet-resident Tregs and block the diabetogenic response.
